Rivaroxaban Impurity 21, identified by the CAS number 1328136-38-4, is a chemical compound associated with the pharmaceutical drug rivaroxaban, which is an anticoagulant used to prevent and treat blood clots. As an impurity, it may arise during the synthesis or storage of rivaroxaban and is typically characterized by its molecular structure, which includes specific functional groups that can influence its chemical behavior and stability. Impurities like this can affect the efficacy and safety of the primary drug, making their identification and quantification important in pharmaceutical development and quality control. The characteristics of Rivaroxaban Impurity 21 would include its molecular weight, solubility in various solvents, and potential reactivity with other compounds. Analytical techniques such as HPLC, NMR, and mass spectrometry are commonly employed to characterize such impurities, ensuring that they are within acceptable limits as defined by regulatory standards. Understanding these characteristics is crucial for maintaining the integrity of the drug formulation and ensuring patient safety.

Rivaroxaban Impurity 21

1328136-38-4: Rivaroxaban Impurity 21, identified by the CAS number 1328136-38-4, is a chemical compound associated with the pharmaceutical drug rivaroxaban, which is an anticoagulant used to prevent and treat blood clots. As an impurity, it may arise during the synthesis or storage of rivaroxaban and is typically characterized by its molecular structure, which includes specific functional groups that can influence its chemical behavior and stability. Impurities like this can affect the efficacy and safety of the primary drug, making their identification and quantification important in pharmaceutical development and quality control. The characteristics of Rivaroxaban Impurity 21 would include its molecular weight, solubility in various solvents, and potential reactivity with other compounds. Analytical techniques such as HPLC, NMR, and mass spectrometry are commonly employed to characterize such impurities, ensuring that they are within acceptable limits as defined by regulatory standards. Understanding these characteristics is crucial for maintaining the integrity of the drug formulation and ensuring patient safety.

CAS 1328136-38-4

Rivaroxaban Impurity 21

Rivaroxaban Impurity 21

Ref: ST-EA-CP-R17086